Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA.
Pharm Res. 2011 Nov;28(11):2669-79. doi: 10.1007/s11095-011-0476-8. Epub 2011 Jun 3.
Mitochondrial oxidative stress and dysfunction have been implicated in the aging process and in numerous chronic diseases. The need for therapies that can protect and/or improve mitochondrial function is obvious. However, the development of mitoprotective drugs has been hampered by a number of challenges, and there are at present no approved therapies for mitochondrial dysfunction. This article describes the original discovery, preclinical development, and clinical development of a novel class of small peptide molecules that selectively target the inner mitochondrial membrane and protect mitochondrial function. These compounds have the potential to be a paradigm-shifting approach to the treatment of mitochondrial dysfunction, which underlies many common diseases, including cardiorenal, neurologic, and metabolic disorders.
线粒体氧化应激和功能障碍与衰老过程和许多慢性疾病有关。显然需要能够保护和/或改善线粒体功能的治疗方法。然而，由于存在许多挑战，线粒体保护药物的开发一直受到阻碍，目前尚无针对线粒体功能障碍的批准疗法。本文描述了一类新型小肽分子的原始发现、临床前开发和临床开发，这些小肽分子选择性地靶向线粒体内膜并保护线粒体功能。这些化合物有可能成为一种改变治疗线粒体功能障碍的方法，而线粒体功能障碍是许多常见疾病的基础，包括心脏肾脏、神经和代谢紊乱。
